Professional, Scientific, and Technical Services Abos

Acumen Pharmaceuticals Inc

ABOS | $3.475 -0.71% -0.72% 150K

(0.0% 1d) (-12.3% 1m) (-13.3% 1y) (0.0% 2d) (-0.9% 3d) (-7.2% 7d) (-32.23% volume)
Earnings Calendar: 2024-03-25
Market Cap: $ 208,777,229
https://www.acumenpharm.com
Sec Filling | Patents | 2021 employees

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.

alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Press-releases

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
ABOS | $3.475 -0.71% -0.72% 150K

Professional, Scientific, and T...

| -5.19% | O: -4.64% H: 3.15% C: 0.29%
acu193 first neurology biomarker pharmaceuticals for meeting

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
ABOS | $3.475 -0.71% -0.72% 150K

Professional, Scientific, and T...

| -9.16% | O: 4.19% H: 2.01% C: -3.52%
disease alzheimer’s treatment pharmaceuticals

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
Published: 2024-03-26 (Crawled : 11:00) - globenewswire.com
ABOS | $3.475 -0.71% -0.72% 150K

Professional, Scientific, and T...

| -18.35% | O: -4.47% H: 4.8% C: -7.64%
business year pharmaceuticals financial results

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
ABOS | $3.475 -0.71% -0.72% 150K

Professional, Scientific, and T...

| -13.47% | O: 5.49% H: 4.02% C: 2.36%
acu193 biomarker pharmaceuticals meeting

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
Published: 2024-03-19 (Crawled : 20:00) - globenewswire.com
ABOS | $3.475 -0.71% -0.72% 150K

Professional, Scientific, and T...

| -12.26% | O: 1.39% H: 0.0% C: 0.0%
report pharmaceuticals financial results

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
ABOS | $3.475 -0.71% -0.72% 150K

Professional, Scientific, and T...

| -16.39% | O: -0.48% H: 5.33% C: 5.33%
pharmaceuticals